Systemic Lupus Erythematosus and Lupus Nephritis: Epidemiology Forecast to 2034

Systemic lupus erythematosus (SLE) is the most common form of lupus. It is an autoimmune disease in which the body’s immune system mistakenly attacks its own healthy cells and organs, leading to inflammation and damage (Centers for Disease Control and Prevention, 2024). SLE is a chronic disease that can affect the skin, joints, blood, and organs such as the kidneys, lungs, and heart. There is currently no cure for SLE, but it can be treated. LN is one of the most serious complications of SLE and often develops within five years of when SLE symptoms first appear (Lupus Foundation of America, 2021).

The symptoms of SLE are joint pain and stiffness throughout the body, fatigue, rashes, and swollen glands, among others. The most common sign of SLE is a red, butterfly-shaped rash over the cheeks and nose that can appear after exposure to sunlight (Mayo Clinic, 2022). The exact cause of SLE is unknown, but scientists believe that certain factors, such as hormones, genetics, and environment, trigger lupus (Centers for Disease Control and Prevention, 2024; Mayo Clinic, 2022). Most SLE patients experience flares - when signs and symptoms get worse for a period and then improve or disappear for some time (Mayo Clinic, 2022). Lupus nephritis (LN) is the most serious complication of SLE. LN develops when lupus antibodies affect the kidneys, causing swelling, irritation, and possible organ damage. LN can damage the kidney’s ability to remove waste from the blood and can lead to blood in urine, protein in the urine, high blood pressure, or kidney failure (Mayo Clinic, 2025).

Report Scope

• This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for SLE and LN in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• The report includes a 10-year epidemiology forecast for the diagnosed prevalent cases of SLE and LN. The diagnosed prevalent cases of SLE and LN are segmented by age and sex. The diagnosed prevalent cases of SLE are also segmented by severity, and the diagnosed prevalent cases of LN are further segmented by class.
• This epidemiology forecast for SLE and LN is supported by data obtained from peer-reviewed articles and population-based studies.
• The forecast methodology was kept consistent across the 7MM to allow for a meaningful comparison of the forecast diagnosed incident and prevalent cases of SLE and LN across these markets.

Reasons to Buy

• The Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) series will allow you to:
• Develop business strategies by understanding the trends shaping and driving the global SLE and LN markets.
• Quantify patient populations in the global SLE and LN markets to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for SLE and LN therapeutics in each of the markets covered.
• Understand magnitude of the SLE and LN population by age, sex, SLE severity and LN class.